Quick Answer
Cytosorbents Corp reported Total Revenue of $22.50 million for fiscal year 2018.
Cytosorbents Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$8.20M +60.4% |
-$20.72M +29.2% |
-$29.25M +10.9% |
-$32.81M -33.6% |
-$24.56M -213.4% |
-$7.84M +59.3% |
| Diluted EPS | -$0.13 +65.8% |
-$0.38 +41.5% |
-$0.65 +13.3% |
-$0.75 -31.6% |
-$0.57 -185.0% |
-$0.20 +66.7% |
| Total Assets | $44.18M -6.1% |
$47.07M -18.1% |
$57.46M -9.1% |
$63.23M -29.4% |
$89.52M -0.5% |
$89.95M +228.5% |
| Cash and Equivalents | $6.25M +90.5% |
$3.28M -76.8% |
$14.13M -36.2% |
$22.14M -57.5% |
$52.14M -27.0% |
$71.42M +483.9% |
| Long-Term Debt | $16.67M +19.1% |
$14.00M +450.4% |
$2.54M -49.1% |
$5.00M | — | $0.00 -100.0% |
| Stockholders Equity | $5.90M -69.9% |
$19.63M -34.4% |
$29.94M -15.4% |
$35.37M -43.5% |
$62.58M -21.0% |
$79.22M +2217.6% |
| R&D Expense | — | — | $15.73M +4.0% |
$15.12M -7.7% |
$16.38M +85.9% |
$8.81M -27.1% |
| Operating Income | -$14.75M +10.4% |
-$16.45M +48.5% |
-$31.95M -1.4% |
-$31.52M -38.6% |
-$22.74M -119.3% |
-$10.37M +45.3% |
| Gross Profit | $26.49M +6.4% |
$24.89M +13.4% |
$21.95M +5.9% |
$20.73M -35.4% |
$32.12M +7.2% |
$29.95M +70.3% |
| Shares Outstanding | 62.80M +14.5% |
54.83M +1.1% |
54.24M +24.3% |
43.64M +0.0% |
43.64M +1.0% |
43.22M +32.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2019 | $6.23M | +8.3% | +20.0% |
| Net Income | September 30, 2025 | -$3.17M | -14.5% | -262.8% |
| Diluted EPS | September 30, 2025 | -$0.05 | +0.0% | -266.7% |
| Total Assets | September 30, 2025 | $45.75M | -4.3% | -4.7% |
| Cash and Equivalents | September 30, 2025 | $7.54M | +32.6% | -26.1% |
| Long-Term Debt | September 30, 2025 | $14.57M | +5.5% | +1.3% |
| Stockholders Equity | September 30, 2025 | $9.02M | -32.6% | -22.1% |
| R&D Expense | September 30, 2024 | $1.85M | -50.6% | +21.8% |
| Operating Income | September 30, 2025 | -$2.86M | +40.7% | +20.8% |
| Gross Profit | September 30, 2025 | $6.67M | +26.8% | -2.2% |
| Shares Outstanding | September 30, 2025 | 62.79M | +15.2% | +0.3% |
- Cytosorbents Corp reported Total Revenue of $22.50 million for fiscal year 2018.
- Cytosorbents Corp showed an increase of +48.5% in Total Revenue compared to the prior fiscal year.
- Cytosorbents Corp reported Net Income of -$8.20 million for fiscal year 2025.
- Cytosorbents Corp showed an increase of +60.4% in Net Income compared to the prior fiscal year.
- Cytosorbents Corp reported Diluted EPS of $0.13 per share (loss) for fiscal year 2025.
- Cytosorbents Corp showed an increase of +65.8% in Diluted EPS compared to the prior fiscal year.
- Cytosorbents Corp reported Total Assets of $44.18 million for fiscal year 2025.
- Cytosorbents Corp showed a decrease of -6.7% in Total Assets compared to the prior fiscal year.
- Cytosorbents Corp reported Cash and Equivalents of $6.25 million for fiscal year 2025.
- Cytosorbents Corp showed an increase of +90.5% in Cash and Equivalents compared to the prior fiscal year.
- Cytosorbents Corp reported Long-Term Debt of $16.67 million for fiscal year 2025.
- Cytosorbents Corp showed an increase of +19.1% in Long-Term Debt compared to the prior fiscal year.
- Cytosorbents Corp reported Stockholders Equity of $5.90 million for fiscal year 2025.
- Cytosorbents Corp showed a decrease of -46.9% in Stockholders Equity compared to the prior fiscal year.
- Cytosorbents Corp reported R&D Expense of $15.73 million for fiscal year 2023.
- Cytosorbents Corp showed an increase of +4.0% in R&D Expense compared to the prior fiscal year.
- Cytosorbents Corp reported Operating Income of -$14.75 million for fiscal year 2025.
- Cytosorbents Corp showed an increase of +10.4% in Operating Income compared to the prior fiscal year.
- Cytosorbents Corp reported Gross Profit of $26.49 million for fiscal year 2025.
- Cytosorbents Corp showed an increase of +6.4% in Gross Profit compared to the prior fiscal year.
- Cytosorbents Corp reported Shares Outstanding of 62.80 million shares for fiscal year 2025.
- Cytosorbents Corp showed an increase of +14.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: